Elypta Drops Data Showing Power Of Metabolite-Based MCED Test
Elypta’s MIRAM kit for multi-cancer early detection performed well in a large-scale study.
You may also be interested in...
An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.
Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.
A selection of articles you may have missed from January 2023, covering the FDA's approach to gene therapies and their long-term implications, the rise (and possible fall) of Chinese companies' efforts in drug development and the ongoing consideration of the 'E' in ESG.